Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). Meeting Abstract

Industry Collaboration

cited authors

  • Fisher, Terrence Lee; Evans, Elizabeth E.; Mallow, Crystal L.; Foster, Amber; Boise, Megan; Smith, Ernest; Leonard, John E.; Chaney, Marya F.; Beck, Joseph Thaddeus; Hager, Steven Jeffrey; Mekhail, Tarek; Seetharamu, Nagashree; Baumgart, Megan; Saba, Nabil F.; Steuer, Conor Ernst; Adkins, Douglas; Burtness, Barbara; Zauderer, Maurice

Publication Date

  • June 1, 2022

webpage

published in

category

start page

  • E18033

end page

  • E18033

volume

  • 40

issue

  • 16